×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Marisa Joubert

Senior Principal Scientist
Process Development

Marisa Joubert is a Senior Principal Scientist and Leader of the Attribute Impact Group in the department of Process Development at Amgen Inc (Thousand Oaks, CA).  She has been at Amgen since 2008 as a pharmaceutical scientist in drug product development.  Her group evaluates the impact of biotherapeutic attributes on the safety and efficacy of drug products.  She is also the team lead of a multi-department cross-functional working group that assesses the risk of immunogenicity of key product quality attributes.  She has received several awards for this work including the 2019 Innovation Award and the 2018 Excellence in Operations Award from Amgen, and the 2015 Ebert Prize from the American Pharmacists Association.  Prior to joining Amgen, she was a Senior Researcher at the Council for Scientific and Industrial Research in Pretoria, South Africa, where she evaluated novel therapeutic agents for treating HIV-1. 

Featured Publications

Zhang Q, Joubert MK, Polozova A, De Guzman R, Lakamsani K, Kinderman K, Xiang D, Shami A, Miscalichi N, Flynn GC, Kuhns S “Glycan Engineering Reveals Interrelated Effects of Terminal Galactose and Core Fucose on Antibody-dependent Cell-mediated Cytotoxicity” 2020 Biotechnol Prog, in press. https://doi.org/10.1002/btpr.3045

Kuhns S, Shu J, Xiang C, De Guzman R, Zhang Q, Bretzlaff W, Miscalichi N, Kalenian K, Joubert MK "Differential Influence on Antibody Dependent Cellular Phagocytosis by Different Glycoforms on Therapeutic Monoclonal Antibodies" 2020 J Biotechnol Vol 317, 5-15. https://doi.org/10.1016/j.jbiotec.2020.04.017

Demmon S, Bhargava S, Ciolek D, Halley J, Jaya N, Joubert MK, Koepf E, Smith P, Trexler-Schmidt M, Tsai P. "A Cross-Industry Forum on Benchmarking Critical Quality Attribute Identification and Linkage to Process Characterization Studies" 2020 Biologicals, in press. https://doi.org/10.1016/j.biologicals.2020.06.008

Jiao N, Barnett GV, Christian TR, Narhi LO, Joh NH, Joubert MK, and Cao S. "Characterization of Subvisible Particles in Biotherapeutic Pre-Filled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock" 2020 J Pharm Sci Vol 109, 640-45. https://doi.org/10.1016/j.xphs.2019.10.066

Joh NH, Thomas L, Christian TR, Verlinsky A, Jiao N, Allotta N, Jawa V, Cao S, Narhi LO, Joubert MK. "Silicone Oil Particles in Pre-filled Syringes with Human Monoclonal Antibody, Representative of Real-World Drug Products, Did Not Increase Immunogenicity in In Vivo and In Vitro Model Systems" 2020 J Pharm Sci Vol 109, 845-53. https://doi.org/10.1016/j.xphs.2019.09.026 

Education

Ph.D., Biochemistry and Molecular Biology, University of California- Los Angeles
B.S., Biochemistry, University of California- Los Angeles